ORLA combined with telerehabilitation in patients with subacute Poststroke aphasia: a randomized controlled trial

ORLA联合远程康复治疗亚急性卒中后失语症患者:一项随机对照试验

阅读:1

Abstract

Oral reading for language in aphasia (ORLA) therapy coupled with telerehabilitation (TR) is a promising adjunct to treatment for aphasia. This single-center, randomized, single-blind, 6-month trial aimed to evaluate whether ORLA combined with TR demonstrates comparable efficacy to conventional ORLA offline rehabilitation for improving comprehensive language ability in subacute aphasia patients while assessing longitudinal treatment effects. Enrolled patients were randomized 1:1:1 into Group A (medium-high intensity ORLA TR), Group B (low-intensity ORLA TR), and Group C (medium-high intensity ORLA offline). All groups received a 6-month, 90-h intervention comprising three treatment phases. The primary outcome was a change in Aphasia Quotient (AQ) at baseline and 4 weeks, 3 months, and 6 months post-treatment. The secondary outcomes included quality of life and language subscale scores at the same time points. A total of 42 participants were analyzed, Group A demonstrated a non-significant mean difference of - 0.62 (95% CI - 5.00 to 6.23; P = 0.825) in AQ compared to Group C. A statistically significant difference in the Stroke Aphasia Quality of Life-39 Scale (SAQOL-39) scores between Group A and Group C (mean difference: - 8.19; 95% CI [- 12.39, - 3.99]; P < 0.001). Group A vs. Group C: No statistically significant differences were observed in any of the aforementioned language subskills between Group A and Group C (P > 0.05 for all comparisons). ORLA combined with TR demonstrated comparable efficacy to conventional ORLA offline rehabilitation, serving as a viable alternative for home-based speech rehabilitation in subacute aphasia patients. This TR approach improved both comprehensive language ability and quality of life, with sustained treatment effects over time.First registration date: August 18, 2023 (retrospective registration, Chinese Clinical Trial Registry number: ChiCTR2300074870).

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。